Virally vectored vaccine delivery: Medical needs, mechanisms, advantages and challenges

Swiss Medical Weekly

Volumn 147, Issue , 2017, Pages

  Pinschewer, Daniel D ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Vaccine; Vector; Virus

Indexed keywords

VACCINE; VIRUS VECTOR; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG SAFETY; GENETIC IMMUNIZATION; HEALTH CARE NEED; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN SYNTHESIS; REVIEW; RISK BENEFIT ANALYSIS; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; GENE VECTOR; IMMUNOLOGY; PROCEDURES; RISK ASSESSMENT; VACCINATION;

ANIMALS; GENETIC VECTORS; HUMANS; RISK ASSESSMENT; VACCINATION; VIRAL VACCINES;

EID: 85027574721     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2017.14465     Document Type: Review

References (100)

1. WHO. Hepatitis B fact sheet. http://wwwwhoint/mediacentre/factsheets/fs204/en/. 2015;(Updated July 2016).
2. WHO. Poliomyelitis fact sheet. http://wwwwhoint/mediacentre/factsheets/fs114/en/. 2015;(Updated July 2016).
3. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;(5):654–65. http://dx.doi.org/10.1086/428404. PubMed.
4. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al.; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;(12):1661–71. http://dx.doi.org/10.1086/508748. PubMed.
5. Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Rossi SL, Fenton K, et al. A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med. 2017;(2):192–9. http://dx.doi.org/10.1038/nm.4253. PubMed.
6. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;(3):334–8. http://dx.doi.org/10.1038/nm.2105. PubMed.
7. Marston HD, Lurie N, Borio LL, Fauci AS. Considerations for Developing a Zika Virus Vaccine. N Engl J Med. 2016;(13):1209–12. http://dx.doi.org/10.1056/NEJMp1607762. PubMed.
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al.; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;(9518):1247–55. http://dx.doi.org/10.1016/S0140-6736(06)68439-0. PubMed.
9. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al.; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;(22):2087–96. http://dx.doi.org/10.1056/NEJMoa1501184.PubMed.
10. Lundstrom K. Alphavirus-based vaccines. Viruses. 2014;(6):2392–415. http://dx.doi.org/10.3390/v6062392. PubMed.
11. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol. 2004;:335–57. http://dx.doi.org/10.1007/978-3-662-05599-1_10. PubMed.
12. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med. 2010;(3):339–45. http://dx.doi.org/10.1038/nm.2104. PubMed.
13. Volz A, Sutter G. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. Adv Virus Res. 2017;:187–243. http://dx.doi.org/10.1016/bs.aivir.2016.07.001. PubMed.
14. Hyvärinen A, Yongabi F, Mäkinen K, Wahlfors J, Pellinen R. Recombination of replicon and helper RNAs and the emergence of propagation-competent vectors upon Sindbis virus vector production. Int J Mol Med. 2013;(2):410–22. doi: http://dx.doi.org/10.3892/ijmm.2013.1395.PubMed.
15. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 1993;(10):5911–21. PubMed.
16. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009;(4):151–7. http://dx.doi.org/10.1016/j.ymgme.2008.12.016. PubMed.
17. Baldo A, Galanis E, Tangy F, Herman P. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother. 2016;(5):1102–16. http://dx.doi.org/10.1080/21645515.2015.1122146. PubMed.
18. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;(6040):813–5. Published online October 06, 1985. http://dx.doi.org/10.1038/317813a0. PubMed.
19. Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010;(8):1440–9. http://dx.doi.org/10.1038/mt.2010.103. PubMed.
20. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;(9):938–43. http://dx.doi.org/10.1038/nm0995-938. PubMed.
21. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016;(17):1647–60. http://dx.doi.org/10.1056/NEJMoa1502924. PubMed.
22. Mandl S, Sigal LJ, Rock KL, Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci USA. 1998;(14):8216–21. http://dx.doi.org/10.1073/pnas.95.14.8216. PubMed.
23. Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, et al.; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015;(1):62–72. http://dx.doi.org/10.1016/j.vaccine.2014.10.004. PubMed.
24. Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005;(2):317–26. http://dx.doi.org/10.1089/vim.2005.18.317. PubMed.
25. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009;(3):293–9. http://dx.doi.org/10.1038/nm.1935. PubMed.
26. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med. 2006;(2):413–24. http://dx.doi.org/10.1084/jem.20051720. PubMed.
27. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA. 2006;(22):8459–64. http://dx.doi.org/10.1073/pnas.0603082103. PubMed.
28. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;(7089):101–5. http://dx.doi.org/10.1038/nature04734. PubMed.
29. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science. 2006;(5801):994–7. http://dx.doi.org/10.1126/science.1132505. PubMed.
30. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science. 2006;(5801):997–1001. http://dx.doi.org/10.1126/science.1132998. PubMed.
31. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;(7454):380–4. http://dx.doi.org/10.1038/nature12306. PubMed.
32. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science. 2013;(6152):1390–4. http://dx.doi.org/10.1126/science.1244040.PubMed.
33. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science. 2013;(6148):903–6. http://dx.doi.org/10.1126/science.1240933.PubMed.
34. Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell. 2013;(5):1094–107. http://dx.doi.org/10.1016/j.cell.2013.04.046.PubMed.
35. Xia P, Wang S, Gao P, Gao G, Fan Z. DNA sensor cGAS-mediated immune recognition. Protein Cell. 2016;(11):777–91. http://dx.doi.org/10.1007/s13238-016-0320-3. PubMed.
36. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity. 2007;(3):370–83. http://dx.doi.org/10.1016/j.immuni.2007.08.012.PubMed.
37. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;(927):258–67. http://dx.doi.org/10.1098/rspb.1957.0048. PubMed.
38. Symons JA, Alcamí A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 1995;(4):551–60. http://dx.doi.org/10.1016/0092-8674(95)90076-4. PubMed.
39. Waibler Z, Anzaghe M, Frenz T, Schwantes A, Pöhlmann C, Ludwig H, et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol. 2009;(4):1563–71. http://dx.doi.org/10.1128/JVI.01617-08. PubMed.
40. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;(6024):1565–70. http://dx.doi.org/10.1126/science.1203486.PubMed.
41. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;(12):823–36. doi: http://dx.doi.org/10.1038/nri3084. PubMed.
42. Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev. 2005;(1):166–83. http://dx.doi.org/10.1111/j.0105-2896.2005.00301.x. PubMed.
43. Probst HC, Lagnel J, Kollias G, van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity. 2003;(5):713–20. http://dx.doi.org/10.1016/S1074-7613(03)00120-1. PubMed.
44. Arima S, Akbar SM, Michitaka K, Horiike N, Nuriya H, Kohara M, et al. Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int J Mol Med. 2003;(2):169–74. PubMed.
45. Freigang S, Probst HC, van den Broek M. DC infection promotes antiviral CTL priming: the ‘Winkelried’ strategy. Trends Immunol. 2005;(1):13–8. http://dx.doi.org/10.1016/j.it.2004.11.013. PubMed.
46. Bernhard CA, Ried C, Kochanek S, Brocker T. CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells. Proc Natl Acad Sci USA. 2015;(17):5461–6. http://dx.doi.org/10.1073/pnas.1423356112. PubMed.
47. Rujas E, Caaveiro JM, Partida-Hanon A, Gulzar N, Morante K, Apellániz B, et al. Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface. Sci Rep. 2016;(1):38177. http://dx.doi.org/10.1038/srep38177.PubMed.
48. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature. 2001;(6836):489–94. http://dx.doi.org/10.1038/35078099. PubMed.
49. Sanderson NS, Zimmermann M, Eilinger L, Gubser C, Schaeren-Wiemers N, Lindberg RL, et al. Cocapture of cognate and bystander antigens can activate autoreactive B cells. Proc Natl Acad Sci USA. 2017;(4):734–9. http://dx.doi.org/10.1073/pnas.1614472114. PubMed.
50. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med. 2016;(17):1635–46. http://dx.doi.org/10.1056/NEJMoa1411627. PubMed.
51. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol. 2000;(3):163–71, discussion 257–344. http://dx.doi.org/10.1006/smim.2000.0253. PubMed.
52. Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci USA. 2015;(10):3050–5. http://dx.doi.org/10.1073/pnas.1500475112.PubMed.
53. Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015;(3):1129–46. http://dx.doi.org/10.1172/JCI78280. PubMed.
54. Sawai ET, Hamza MS, Ye M, Shaw KE, Luciw PA. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J Virol. 2000;(4):2038–45. http://dx.doi.org/10.1128/JVI.74.4.2038-2045.2000. PubMed.
55. Moliva JI, Turner J, Torrelles JB. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine. 2015;(39):5035–41. http://dx.doi.org/10.1016/j.vaccine.2015.08.033.PubMed.
56. Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol (Berl). 2015;(3):247–54. http://dx.doi.org/10.1007/s00430-015-0388-z. PubMed.
57. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al., RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;(20):1863–75. http://dx.doi.org/10.1056/NEJMoa1102287. PubMed.
58. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;(5408):1748–52. http://dx.doi.org/10.1126/science.283.5408.1748. PubMed.
59. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogres-sors. Proc Natl Acad Sci USA. 2000;(6):2709–14. http://dx.doi.org/10.1073/pnas.050567397. PubMed.
60. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology. 2006;(3):563–72. Published online February 24, 2006. http://dx.doi.org/10.1002/hep.21049. PubMed.
61. Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmaurice K, Oniangue-Ndza C, et al. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology. 2010;(1):54–62. Published online December 25, 2009. http://dx.doi.org/10.1002/hep.23275. PubMed.
62. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 2009;(4):e1000392. http://dx.doi.org/10.1371/journal.ppat.1000392. PubMed.
63. Fernandez-Ruiz D, Ng WY, Holz LE, Ma JZ, Zaid A, Wong YC, et al. Liver-Resident Memory CD8(+) T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. Immunity. 2016;(4):889–902. http://dx.doi.org/10.1016/j.immuni.2016.08.011. PubMed.
64. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;(4):422–34. http://dx.doi.org/10.1093/oxfordjournals.aje.a120955.PubMed.
65. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis. 1979;(4):527–33. http://dx.doi.org/10.1093/infdis/140.4.527. PubMed.
66. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;(1):587–619. http://dx.doi.org/10.1146/annurev-immunol-031210-101315. PubMed.
67. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA. 1967;(12):1075–80. http://dx.doi.org/10.1001/jama.1967.03130250057008. PubMed.
68. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, et al.; VSV-Ebola Consortium. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;(10):1156–66. http://dx.doi.org/10.1016/S1473-3099(15)00154-1.PubMed.
69. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;(9996):857–66. http://dx.doi.org/10.1016/S0140-6736(15)61117-5. PubMed.
70. Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis. 2011;(Suppl 3):S785–90. http://dx.doi.org/10.1093/infdis/jir298.PubMed.
71. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;(1):e2. http://dx.doi.org/10.1371/journal.ppat.0030002. PubMed.
72. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987;(3):437–44. http://dx.doi.org/10.1093/infdis/155.3.437.PubMed.
73. Lukashevich IS. Advanced vaccine candidates for Lassa fever. Viruses. 2012;(11):2514–57. http://dx.doi.org/10.3390/v4112514. PubMed.
74. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al.; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;(9951):1358–65. http://dx.doi.org/10.1016/S0140-6736(14)61060-6. PubMed.
75. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al.; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;(2):113–23. http://dx.doi.org/10.1056/NEJMoa1411037. PubMed.
76. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;(9276):98–104. http://dx.doi.org/10.1016/S0140-6736(01)05327-2. PubMed.
77. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al.; Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;(9276):91–7. http://dx.doi.org/10.1016/S0140-6736(01)05326-0. PubMed.
78. WHO. Dengue vaccine: WHO position paper – July 2016. http://wwwwhoint/wer/2016/wer9130pdf?ua=1. 2016.
79. Hansen SG, Piatak M, Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013;(7469):100–4. http://dx.doi.org/10.1038/nature12519. PubMed.
80. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;(25):2780–8. http://dx.doi.org/10.1200/JCO.2014.58.3377.PubMed.
81. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;(5):501–8. http://dx.doi.org/10.1016/S1470-2045(12)70006-2. PubMed.
82. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;(5):509–17. http://dx.doi.org/10.1016/S1470-2045(12)70007-4. PubMed.
83. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;(8):711–23. http://dx.doi.org/10.1056/NEJMoa1003466. PubMed.
84. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;(7):1099–105. http://dx.doi.org/10.1200/JCO.2009.25.0597.PubMed.
85. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;(226):226ra32. http://dx.doi.org/10.1126/scitranslmed.3008095. PubMed.
86. Smith GL, Mackett M, Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983;(5908):490–5. http://dx.doi.org/10.1038/302490a0. PubMed.
87. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA. 1982;(23):7415–9. http://dx.doi.org/10.1073/pnas.79.23.7415. PubMed.
88. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010;(1):62–73. http://dx.doi.org/10.1038/nrmicro2240. PubMed.
89. Quirk EK, Mogg R, Brown DD, Lally MA, Mehrotra DV, DiNubile MJ, et al. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine. Clin Infect Dis. 2008;(12):1593–9. http://dx.doi.org/10.1086/593313. PubMed.
90. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al.; Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;(9653):1894–905. http://dx.doi.org/10.1016/S0140-6736(08)61592-5. PubMed.
91. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther. 2008;(9):1609–16. http://dx.doi.org/10.1038/mt.2008.141. PubMed.
92. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;(7090):239–43. http://dx.doi.org/10.1038/nature04721. PubMed.
93. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;(11):7179–85. http://dx.doi.org/10.4049/jimmunol.174.11.7179. PubMed.
94. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;(10):6290–7. http://dx.doi.org/10.4049/jimmunol.172.10.6290.PubMed.
95. Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, et al. Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. Vaccine. 2017;(1):1–9. http://dx.doi.org/10.1016/j.vaccine.2016.11.063.PubMed.
96. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther. 2008;(1):16–29. http://dx.doi.org/10.1038/sj.mt.6300321. PubMed.
97. Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther. 2014;(2):420–9. http://dx.doi.org/10.1038/mt.2013.249. PubMed.
98. Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol. 2012;(15):7760–70. http://dx.doi.org/10.1128/JVI.00599-12. PubMed.
99. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010;(12):6033–40. http://dx.doi.org/10.1128/JVI.02690-09. PubMed.
100. Komor AC, Badran AH, Liu DR. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. 2017;(1-2):20–36. http://dx.doi.org/10.1016/j.cell.2016.10.044. PubMed.